2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Y Tan, Z Zhang, C Zheng, KA Wintergerst… - Nature Reviews …, 2020 - nature.com
The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied
in the past decade, but effective approaches to prevent and treat this disease are limited …
in the past decade, but effective approaches to prevent and treat this disease are limited …
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen - Nature reviews endocrinology, 2020 - nature.com
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the …
F Cosentino, CP Cannon, DZI Cherney… - Circulation, 2020 - Am Heart Assoc
Background: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2
inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of …
inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of …
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart …
K Damman, JC Beusekamp… - European journal of …, 2020 - Wiley Online Library
Aims Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and
heart failure (HF) admissions in patients with chronic HF. However, safety and clinical …
heart failure (HF) admissions in patients with chronic HF. However, safety and clinical …
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …
Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
Background Several trials have demonstrated protective effects from inhibition of sodium‐
glucose cotransporter 2 among patients with type 2 diabetes mellitus. There is uncertainty …
glucose cotransporter 2 among patients with type 2 diabetes mellitus. There is uncertainty …
Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update
L Lipscombe, S Butalia, K Dasgupta, DT Eurich… - Canadian journal of …, 2020 - Elsevier
Methods The overarching goals and methodologic principles for the Diabetes Canada CPG
are unchanged from 2018 (2, 3). Leveraging the search methods and PICO questions used …
are unchanged from 2018 (2, 3). Leveraging the search methods and PICO questions used …